| Filed On | Filing |
|---|---|
| 10 Nov 2026 | 10-Q |
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. ET |
| 15 Oct 2026 | SCHEDULE 13G |
| 09 Sep 2026 |
Form 4: Schwartz Aharon, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Naos Yaron, Sr. VP & COO
Granted 112,000 Stock Option (Right to Buy) · Granted 56,000 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Elze Christian, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Melincoff Gwen A, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Boudes Pol F, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Bashan Dror, Director
Granted 320,000 Stock Option (Right to Buy) · Granted 160,000 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Bar-Shalev Amos, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Ben Zvi Shmuel, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 04 Sep 2026 |
Form 4: Forster Eliot, Director
Granted 17,000 Stock Options (Right to Buy) · Granted 8,500 Restricted Stock Units |
| 12 Aug 2026 | FORM S-8 |
| 12 Aug 2026 | 10-Q |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EDT |
| 29 Jul 2026 | SCHEDULE 13G |
| 25 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
1.Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel, to provide additional incentives to Employees, Directors and Consultants and to promote the success of the Company’s business. |
| 21 May 2026 |
8-K: Regulation FD Disclosure
1 PROTALIX BIOTHERAPEUTICS C O R P O R A T E P R E S E N T A T I O N J u n e 2024 PROTALIX BIOTHERAPEUTICS Pioneering solutions to transform the treatment of rare diseases C O R P O R A T E P R E S E N T A T I O N M a y 2026 |
| 13 May 2026 | 10-Q |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition
Company to host conference call and webcast today at 8:00 a.m. EDT |
Loading...